Cite
HARVARD Citation
Johansson, E. et al. (2018). Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. Journal of medical economics. pp. 810-820. [Online].